Australia spends about A$1.6 billion a year on diabetes-related foot disease—roughly the cost of building Brisbane’s 359-bed Queensland Children’s (formerly Lady Cilento) Hospital, every single year. Shift extras money to GP gap cover and that burden will swell, because podiatry is treated as a luxury, not essential care.
Author attribution not recorded
The hidden vulnerability
Australia spends about A$1.6 billion a year on diabetes-related foot disease—roughly the cost of building Brisbane’s 359-bed Queensland Children’s (formerly Lady Cilento) Hospital, every single year. Shift extras money to GP gap cover and that burden will swell, because podiatry is treated as a luxury, not essential care.
Unlike GPs and medical specialists, podiatrists cannot bill Medicare directly. Instead, patients must rely on private health insurance extras cover or a limited Medicare mechanism called Chronic Disease Management (CDM)—a shared pool of up to five subsidised allied health visits per year, split across 13 professions. Once this is exhausted, extras cover becomes the only realistic way to afford regular podiatric care.
The funding proposal with a sting
Private health insurers are lobbying to pay patients’ GP out-of-pocket costs. It sounds benign—what’s wrong with cheaper doctor visits? Until you follow the money. Funds want to bankroll those gaps from the existing extras pool. According to the Australian Prudential Regulation Authority, insurers financed 110 million allied-health services last year. Divert even one-fifth of that spend to GP gaps and something must give. Dental and optical enjoy heavyweight lobbying clout; podiatry, usually buried in policy fine print under “other services”, will be the first category trimmed.
Why podiatrists are worried
A typical mid-tier extras policy refunds around $350–$450 a year for podiatry, enough for four consultations once the CDM allowance has evaporated. If that cap shrinks, patients stretch reviews from six weeks to six months. Pressure lesions are missed; ulcers brew unseen; avoidable hospital presentations spike. Nationally we already spend about A$1.6 billion a year treating diabetic foot disease. Shifting preventive foot-care dollars to GP co-payments is a textbook false economy that will swell this figure still further.
Prevention is brutally cost-effective: regular debridement, footwear optimisation and early offloading avert infections and admissions that cost multiples of a year’s extras benefits. Starving this work doesn’t save money; it shifts it into hospital wards, where the bill is larger and the outcomes are worse.
Foot disease also drives some of the cruellest inequities in Australian health. Aboriginal and Torres Strait Islander Australians with diabetes are 38 times more likely to undergo a major lower-limb amputation than their non-Indigenous peers, yet are far less likely to hold comprehensive insurance. When extras limits contract, the choice becomes brutal: pay out-of-pocket or forgo care. What is marketed in Canberra as “consumer choice” manifests in Broome and Bourke as limb loss. Rural Australians, shift workers and casual employees will feel the pinch next.
The vertical-integration threat
Private-equity groups have read the tea leaves. In March, US firm KKR tipped $300 million into the Family Doctor chain, a GP roll-up that now owns more than 110 clinics. Two months later Bupa, both insurer and provider, announced plans to control 130 surgeries within three years. If an insurer both owns the practice and pays the gap, every referral becomes an internal upsell. Slow, complex and resource-hungry diabetic feet will not win that internal bidding war.
Debt-fuelled health empires are not hypothetical. Private-hospital operator Healthscope collapsed into receivership in May under $1.6 billion in liabilities after an aggressive sale-and-leaseback spree. When leveraged operators topple, public hospitals catch the overflow and taxpayers foot the bill. A vertically integrated GP-insurer model would expose primary care to the same boom-bust cycle, only this time the casualties would arrive on infected feet instead of in surgical gowns.
International evidence
A 2025 Brown University–led JAMA Health Forum analysis of 226 million commercial price records found negotiated fees for a standard primary care office visit were about 11% higher at hospital-owned practices and about 8% higher at private equity–owned practices than at independent clinics. That’s what consolidation does to prices—even before you add incentives to preferentially funnel patients within the chain.
What Canberra should do
Hold the line on section 126 of the Health Insurance Act 1973. It prohibits insurance for out-of-hospital services that attract a Medicare benefit (i.e., GP care), except for hospital or hospital-substitute treatment. Breach it once and managed care will seep into every specialty.
Double the CDM quota to ten allied health visits and index the rebate properly. Spread across 13 disciplines, the current five-visit cap is a rationing device, not policy. Ten Medicare-funded podiatry visits (~$620 in total Medicare benefits) cost far less than one below-knee amputation (median ~A$23.6k), before rehab and lost productivity.
Tie profit to reinvestment. Any group earning more than half its revenue from Medicare should reinvest a fixed share into Australian health infrastructure instead of siphoning dividends offshore.
Shine a light on money flows. Publish clinic-level insurer payments so the public can see, in real time, whether allied-health rebates are being siphoned to plug GP gaps. Transparency deters quiet cannibalisation.
Feet first
Health policy should start at ground level. Protect the foot and you safeguard mobility, productivity and, ultimately, the budget. Ignore the foot and the entire body, physical and fiscal, soon follows it into avoidable ruin. The path ahead is clear: keep insurers out of GP gaps, strengthen preventive funding, and let Australians keep putting one healthy foot in front of the other.